2025
SJR Q3
JCR Q3 · 1,8
6 eşleşen makale
SCIE
Dergi ayrıntısı
Assay and Drug Development Technologies
- Yayıncı
- Mary Ann Liebert Inc.
- Ülke
- United States · Northern America
- Tür
- journal
- ISSN
-
1540658X15578127
Bütünleşik değerlendirme
Scopus tarafı Scimago SJR; WoS tarafı Master Journal List + JCR/JIF. Kaynaklar ISSN üzerinden eşleştirilir. WoS / JCR metrikleri yalnızca 1997 ve sonrası yıllar için vardır.
WoS / JCR verileri 1997 ve sonrası içindir.
Scopus
Scopus · Scimago
- SJR 0,327
- Quartile Q3
- H-Index 68
- Atıf/yayın 2,3
- Doküman (3y) 98
- Atıf (3y) 202
Clarivate
Web of Science · JCR · 2025
- JCR Q Q3
- JIF 1,8
- 5Y JIF 1,9
- JCI 0,43
WoS indeksleri
- SCIE
Konu sınıflandırması
Kategoriler (SJR)
- Drug Discovery Q3
- Molecular Medicine Q4
Alanlar
- Biochemistry, Genetics and Molecular Biology
- Pharmacology, Toxicology and Pharmaceutics
WoS kategorileri
- Biochemical Research Methods | Pharmacology & Pharmacy
Yıllık quartile karşılaştırması
Scimago (SJR) tüm yıllar; Clarivate (JCR / JIF / JCI) 1997 ve sonrası. Güncel yıl açık; diğer yıllar kapalıdır.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q3 | Q3 | 0,327 | 1,8 | 1,9 | 0,43 | Q3 | 68 |
| 2024 | Q3 | Q3 | 0,308 | 1,7 | 1,9 | 0,41 | Q4 | 67 |
| 2023 | Q3 | Q3 | 0,317 | 1,6 | 2,2 | 0,45 | Q3 | 67 |
| 2022 | Q3 | Q4 | 0,358 | 1,8 | 1,8 | 0,5 | Q3 | 67 |
| 2021 | Q3 | Q3 | 0,394 | 2,5 | 1,8 | 0,45 | Q3 | 67 |
| 2020 | Q3 | Q4 | 0,402 | 1,7 | 1,7 | 0,46 | Q3 | 67 |
| 2019 | Q2 | Q4 | 0,568 | 1,2 | 2,4 | 0,46 | Q3 | 67 |
| 2018 | — | Q4 | — | 1,4 | 2,3 | 0,49 | Q3 | — |
| 2017 | Q1 | Q4 | 1,033 | 1,6 | 2,1 | 0,63 | Q3 | 67 |
| 2016 | Q2 | Q3 | 0,869 | 2,2 | 2,3 | — | — | 67 |
| 2015 | Q2 | Q3 | 0,843 | 1,7 | 1,9 | — | — | 67 |
| 2014 | Q1 | Q3 | 0,975 | 1,5 | 1,9 | — | — | 67 |
| 2013 | Q2 | Q3 | 0,964 | 2,1 | 1,9 | — | — | 67 |
| 2012 | Q2 | Q3 | 0,834 | 1,9 | 2 | — | — | 67 |
| 2011 | Q2 | Q3 | 0,656 | 1,7 | 1,7 | — | — | 67 |
| 2010 | Q2 | Q2 | 0,966 | 2,7 | 2,6 | — | — | 67 |
| 2009 | — | Q2 | — | 2,7 | 2,6 | — | — | — |
| 2008 | — | Q2 | — | 2,4 | 2,5 | — | — | — |
| 2007 | — | Q3 | — | 1,8 | 2,1 | — | — | — |
| 2006 | — | Q2 | — | 2,5 | — | — | — | — |
| 2005 | — | Q2 | — | 2,1 | — | — | — | — |
| 2004 | — | Q3 | — | 1,3 | — | — | — | — |
| 2003 | — | Q2 | — | 1,9 | — | — | — | — |
JCR kategori quartile geçmişi
Yıla ve kategoriye göre JCR / JCI quartile. 1997 ve sonrası.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | Kategori | Edition | JCR Q (1997+) | JCI Q (1997+) | Sıra |
|---|---|---|---|---|---|
| 2025 | BIOCHEMICAL RESEARCH METHODS | SCIE | Q4 | Q4 | 67/85 |
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 258/356 |
| 2024 | BIOCHEMICAL RESEARCH METHODS | SCIE | Q4 | Q4 | 66/86 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q4 | 256/352 |
| 2023 | BIOCHEMICAL RESEARCH METHODS | SCIE | Q4 | Q4 | 69/85 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 259/354 |
| 2022 | BIOCHEMICAL RESEARCH METHODS | SCIE | Q4 | Q3 | 64/77 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q3 | 231/278 |
| 2021 | BIOCHEMICAL RESEARCH METHODS | SCIE | Q4 | Q4 | 61/79 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 207/279 |
| 2020 | BIOCHEMICAL RESEARCH METHODS | SCIE | Q4 | Q4 | 68/78 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q3 | 236/276 |
| 2019 | BIOCHEMICAL RESEARCH METHODS | SCIE | Q4 | Q4 | 72/77 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q3 | 246/271 |
| 2018 | BIOCHEMICAL RESEARCH METHODS | SCIE | Q4 | Q3 | 68/79 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q3 | 224/267 |
| 2017 | BIOCHEMICAL RESEARCH METHODS | SCIE | Q4 | Q3 | 61/79 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q3 | 204/261 |
| 2016 | BIOCHEMICAL RESEARCH METHODS | SCIE | Q3 | — | 46/78 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 150/257 |
| 2015 | BIOCHEMICAL RESEARCH METHODS | SCIE | Q3 | — | 55/77 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 178/255 |
| 2014 | BIOCHEMICAL RESEARCH METHODS | SCIE | Q4 | — | 61/79 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 181/255 |
| 2013 | BIOCHEMICAL RESEARCH METHODS | SCIE | Q3 | — | 47/78 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 146/256 |
| 2012 | BIOCHEMICAL RESEARCH METHODS | SCIE | Q3 | — | 50/75 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 160/261 |
| 2011 | BIOCHEMICAL RESEARCH METHODS | SCIE | Q3 | — | 53/72 |
| 2011 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 164/261 |
| 2010 | BIOCHEMICAL RESEARCH METHODS | SCIE | Q2 | — | 30/71 |
| 2010 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 95/252 |
| 2009 | BIOCHEMICAL RESEARCH METHODS | SCIE | Q2 | — | 25/67 |
| 2009 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 91/237 |
| 2008 | BIOCHEMICAL RESEARCH METHODS | SCIE | Q2 | — | 30/65 |
| 2008 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 102/219 |
| 2007 | BIOCHEMICAL RESEARCH METHODS | SCIE | Q3 | — | 40/60 |
| 2007 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 119/205 |
| 2006 | BIOCHEMICAL RESEARCH METHODS | SCIE | Q2 | — | 27/56 |
| 2006 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 70/199 |
| 2005 | BIOCHEMICAL RESEARCH METHODS | SCIE | Q3 | — | 27/53 |
| 2005 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 87/193 |
| 2004 | BIOCHEMICAL RESEARCH METHODS | SCIE | Q3 | — | 36/51 |
| 2004 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 120/187 |
| 2003 | BIOCHEMICAL RESEARCH METHODS | SCIE | Q3 | — | 27/51 |
| 2003 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 81/185 |